Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Bristol Myers Squibb Co (BMY)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Bristol Myers Squibb Co.
Table 2 shows the detailed insider transactions.
This company's CIK number is 14272.
Total stock buying since 2015: $3,732,641.
Total stock sales since 2015: $206,100,092.
Total stock option exercises since 2015: $70,354,798.
Table 3. Detailed insider trading at Bristol Myers Squibb Co (BMY)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-09-02 | Elkins David V (EVP, Chief Financial Officer) | Sale | 56,000 | 47.33 | 2,650,480 |
| 2025-09-01 | Short Bartie Wendy (EVP, Corporate Affairs) | Option Ex | 1,235 | .00 | 0 |
| 2025-08-02 | Short Bartie Wendy (EVP, Corporate Affairs) | Sale | 378 | 44.23 | 16,718 |
| 2025-08-02 | Short Bartie Wendy (EVP, Corporate Affairs) | Option Ex | 738 | .00 | 0 |
| 2025-08-01 | Gallman Cari (EVP, General Counsel) | Option Ex | 1,061 | .00 | 0 |
| 2025-06-03 | Short Bartie Wendy (EVP, Corporate Affairs) | Option Ex | 8,040 | .00 | 0 |
| 2025-05-09 | Hickey Benjamin (President, RayzeBio Org.) | Sale | 97 | 38.01 | 3,686 |
| 2025-04-01 | Shanahan Karin (EVP, Glob. Prod. Dev. & Supply) | Option Ex | 3,306 | .00 | 0 |
| 2025-03-10 | Holzer Phil M (SVP and Controller) | Option Ex | 7,140 | .00 | 0 |
| 2025-03-10 | Hoch Lynelle (President, Cell Therapy Org.) | Option Ex | 7,446 | .00 | 0 |
| 2025-03-10 | Poole Ahn Amanda (EVP, Chief People Officer) | Option Ex | 7,164 | .00 | 0 |
| 2025-03-10 | Gallman Cari (EVP, Corporate Affairs) | Option Ex | 7,588 | .00 | 0 |
| 2025-03-10 | Lenkowsky Adam (EVP, Chief Commercial Officer) | Option Ex | 16,684 | .00 | 0 |
| 2025-03-10 | Shanahan Karin (EVP, Glob. Prod. Dev. & Supply) | Option Ex | 20,423 | .00 | 0 |
| 2025-03-10 | Meyers Gregory Scott (EVP, Chief Digital & Tech Off.) | Option Ex | 23,150 | .00 | 0 |
| 2025-03-10 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 44,098 | .00 | 0 |
| 2025-03-10 | Plenge Robert M (EVP, Chief Research Officer) | Option Ex | 11,255 | .00 | 0 |
| 2025-03-10 | Boerner Christopher S. (Chief Executive Officer) | Option Ex | 60,034 | .00 | 0 |
| 2025-03-10 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 69,517 | .00 | 0 |
| 2025-03-10 | Leung Sandra (EVP, General Counsel) | Option Ex | 48,718 | .00 | 0 |
| 2025-02-20 | Boerner Christopher S. (Chief Executive Officer) | Buy | 2,000 | 55.05 | 110,096 |
| 2025-02-14 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Buy | 1,823 | 54.84 | 99,973 |
| 2025-02-01 | Meyers Gregory Scott (EVP, Chief Digital & Tech Off.) | Option Ex | 2,543 | .00 | 0 |
| 2025-02-01 | Hickey Benjamin (President, RayzeBio Org.) | Option Ex | 10,078 | .00 | 0 |
| 2024-11-04 | Holzer Phil M (SVP and Controller) | Sale | 700 | 55.62 | 38,930 |
| 2024-11-01 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Buy | 1,830 | 54.67 | 100,055 |
| 2024-11-01 | Boerner Christopher S. (Chief Executive Officer) | Option Ex | 2,964 | .00 | 0 |
| 2024-10-02 | Gallman Cari (EVP, Corporate Affairs) | Option Ex | 4,558 | .00 | 0 |
| 2024-08-01 | Gallman Cari (EVP, Corporate Affairs) | Option Ex | 1,061 | .00 | 0 |
| 2024-04-01 | Shanahan Karin (EVP, Glob. Prod. Dev. & Supply) | Option Ex | 3,306 | .00 | 0 |
| 2024-03-10 | Holzer Phil M (SVP and Controller) | Option Ex | 5,520 | .00 | 0 |
| 2024-03-10 | Hoch Lynelle (President, Cell Therapy Org.) | Option Ex | 4,351 | .00 | 0 |
| 2024-03-10 | Poole Ahn Amanda (EVP, Chief Human Resources) | Option Ex | 5,458 | .00 | 0 |
| 2024-03-10 | Gallman Cari (EVP, Corporate Affairs) | Option Ex | 2,761 | .00 | 0 |
| 2024-03-10 | Lenkowsky Adam (EVP, Chief Commercial Officer) | Option Ex | 15,016 | .00 | 0 |
| 2024-03-10 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 38,388 | .00 | 0 |
| 2024-03-10 | Plenge Robert M (EVP, Chief Research Officer) | Option Ex | 9,143 | .00 | 0 |
| 2024-03-10 | Boerner Christopher S. (Chief Executive Officer) | Option Ex | 54,638 | .00 | 0 |
| 2024-03-10 | Caforio Giovanni (Executive Chair of the Board) | Option Ex | 190,130 | .00 | 0 |
| 2024-03-10 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 64,326 | .00 | 0 |
| 2024-03-10 | Leung Sandra (EVP, General Counsel) | Option Ex | 46,784 | .00 | 0 |
| 2024-02-01 | Meyers Gregory Scott (EVP, Chief Digital & Tech Off.) | Option Ex | 2,543 | .00 | 0 |
| 2023-12-05 | Boerner Christopher S. (Chief Executive Officer) | Buy | 2,000 | 49.78 | 99,560 |
| 2023-12-02 | Plenge Robert M (EVP, Chief Research Officer) | Option Ex | 616 | .00 | 0 |
| 2023-12-02 | Boerner Christopher S. (Chief Executive Officer) | Option Ex | 2,638 | .00 | 0 |
| 2023-12-02 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 8,792 | .00 | 0 |
| 2023-11-28 | Boerner Christopher S. (Chief Executive Officer) | Buy | 3,071 | 48.86 | 150,049 |
| 2023-11-20 | Samuels Theodore R. Ii (Director) | Buy | 8,500 | 49.81 | 423,385 |
| 2023-08-24 | Powell Ann (EVP, Chief Human Resources) | Sale | 17,986 | 61.25 | 1,101,642 |
| 2023-08-03 | Plenge Robert M (EVP, Chief Research Officer) | Sale | 732 | 61.14 | 44,754 |
| 2023-07-01 | Weese Michelle (EVP, Corporate Affairs) | Option Ex | 1,885 | .00 | 0 |
| 2023-07-01 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 9,357 | .00 | 0 |
| 2023-06-03 | Lenkowsky Adam (EVP, Chief Commercial Officer) | Option Ex | 1,077 | .00 | 0 |
| 2023-05-03 | Vessey Rupert (EVP & President, Research) | Sale | 50,385 | 67.06 | 3,378,818 |
| 2023-05-02 | Greenlees Sharon (SVP & Controller) | Option Ex | 1,017 | .00 | 0 |
| 2023-04-01 | Shanahan Karin (EVP, Glob. Prod. Dev. & Supply) | Option Ex | 3,306 | .00 | 0 |
| 2023-04-01 | Mily Elizabeth (EVP, Strategy & BD) | Option Ex | 6,346 | .00 | 0 |
| 2023-03-10 | Shanahan Karin (EVP, Glob. Prod. Dev. & Supply) | Option Ex | 2,447 | .00 | 0 |
| 2023-03-10 | Meyers Gregory Scott (EVP, Chief Digital & Tech Off.) | Option Ex | 2,836 | .00 | 0 |
| 2023-03-10 | Weese Michelle (EVP, Corporate Affairs) | Option Ex | 1,590 | .00 | 0 |
| 2023-03-10 | Mily Elizabeth (EVP, Strategy & BD) | Option Ex | 29,636 | .00 | 0 |
| 2023-03-10 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 38,978 | .00 | 0 |
| 2023-03-10 | Vessey Rupert (EVP & President, Research) | Option Ex | 66,935 | .00 | 0 |
| 2023-03-10 | Powell Ann (EVP, Chief Human Resources) | Option Ex | 34,447 | .00 | 0 |
| 2023-03-10 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Option Ex | 59,111 | .00 | 0 |
| 2023-03-10 | Caforio Giovanni (Board Chair and CEO) | Option Ex | 234,676 | .00 | 0 |
| 2023-03-10 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 71,871 | .00 | 0 |
| 2023-03-10 | Leung Sandra (EVP, General Counsel) | Option Ex | 57,990 | .00 | 0 |
| 2023-02-06 | Powell Ann (EVP, Chief Human Resources) | Sale | 11,183 | 74.69 | 835,258 |
| 2023-02-06 | Caforio Giovanni (Board Chair and CEO) | Sale | 240,000 | 74.65 | 17,916,000 |
| 2023-02-01 | Meyers Gregory Scott (EVP, Chief Digital & Tech Off.) | Option Ex | 2,543 | .00 | 0 |
| 2022-12-02 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 8,792 | .00 | 0 |
| 2022-12-02 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Option Ex | 2,637 | .00 | 0 |
| 2022-12-02 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 8,792 | .00 | 0 |
| 2022-11-09 | Powell Ann (EVP, Chief Human Resources) | Sale | 16,250 | 80.45 | 1,307,312 |
| 2022-11-07 | Vessey Rupert (EVP, Research & Early Dev.) | Sale | 45,910 | 78.88 | 3,621,380 |
| 2022-11-07 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 52,604 | 54.85 | 2,885,118 |
| 2022-09-20 | Caforio Giovanni (Board Chair and CEO) | Sale | 25,000 | 69.71 | 1,742,749 |
| 2022-09-14 | Powell Ann (EVP, Chief Human Resources) | Sale | 25,000 | 70.75 | 1,768,750 |
| 2022-09-13 | Elkins David V (EVP, Chief Financial Officer) | Sale | 133,951 | 71.32 | 9,553,385 |
| 2022-09-13 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 123,277 | 48.49 | 5,977,701 |
| 2022-07-01 | Weese Michelle (EVP, Corporate Affairs) | Option Ex | 1,885 | .00 | 0 |
| 2022-07-01 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 9,356 | .00 | 0 |
| 2022-06-13 | Caforio Giovanni (Board Chair and CEO) | Sale | 30,000 | 74.04 | 2,221,200 |
| 2022-06-06 | Leung Sandra (EVP, General Counsel) | Sale | 65,000 | 74.89 | 4,867,850 |
| 2022-06-03 | Haller Julia A | Option Ex | 2,949 | .00 | 0 |
| 2022-04-01 | Mily Elizabeth (EVP, Strategy & BD) | Option Ex | 6,347 | .00 | 0 |
| 2022-03-21 | Caforio Giovanni (Board Chair and CEO) | Sale | 25,000 | 71.52 | 1,788,000 |
| 2022-03-16 | Vessey Rupert (EVP, Research & Early Dev.) | Sale | 74,559 | 69.25 | 5,163,210 |
| 2022-03-16 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 47,305 | 53.64 | 2,537,582 |
| 2022-03-14 | Santiago Karen Murphy (SVP & Controller) | Sale | 6,577 | 69.19 | 455,095 |
| 2022-03-14 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Sale | 29,532 | 69.20 | 2,043,525 |
| 2022-03-10 | Mily Elizabeth (EVP, Strategy & BD) | Option Ex | 4,005 | .00 | 0 |
| 2022-03-10 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 9,074 | .00 | 0 |
| 2022-03-10 | Santiago Karen Murphy (SVP & Controller) | Option Ex | 11,073 | .00 | 0 |
| 2022-03-10 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 15,247 | .00 | 0 |
| 2022-03-10 | Powell Ann (EVP, Chief Human Resources) | Option Ex | 35,686 | .00 | 0 |
| 2022-03-10 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Option Ex | 51,715 | .00 | 0 |
| 2022-03-10 | Caforio Giovanni (Board Chair and CEO) | Option Ex | 239,501 | .00 | 0 |
| 2022-03-10 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 16,067 | .00 | 0 |
| 2022-03-10 | Leung Sandra (EVP, General Counsel) | Option Ex | 60,273 | .00 | 0 |
| 2022-03-01 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 23,350 | .00 | 0 |
| 2022-03-01 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 24,577 | .00 | 0 |
| 2022-02-04 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 3,593 | .00 | 0 |
| 2021-12-16 | Vessey Rupert (EVP, Research & Early Dev.) | Sale | 19,298 | 61.99 | 1,196,244 |
| 2021-12-02 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 8,792 | .00 | 0 |
| 2021-12-02 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Option Ex | 2,638 | .00 | 0 |
| 2021-12-02 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 8,792 | .00 | 0 |
| 2021-11-24 | Von Autenried Paul (EVP, Chief Information Officer) | Sale | 17,353 | 56.92 | 987,732 |
| 2021-11-23 | Von Autenried Paul (EVP, Chief Information Officer) | Sale | 15,418 | 57.47 | 886,072 |
| 2021-11-22 | Von Autenried Paul (EVP, Chief Information Officer) | Sale | 18,363 | 57.17 | 1,049,812 |
| 2021-09-20 | Caforio Giovanni (Board Chair and CEO) | Sale | 25,000 | 60.64 | 1,516,000 |
| 2021-08-12 | Elkins David V (EVP, Chief Financial Officer) | Sale | 99,691 | 66.94 | 6,673,315 |
| 2021-08-12 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 70,000 | 48.49 | 3,394,300 |
| 2021-08-03 | Powell Ann (EVP, Chief Human Resources) | Sale | 23,280 | 68.57 | 1,596,309 |
| 2021-08-02 | Caforio Giovanni (Chairman and CEO) | Sale | 20,000 | 68.58 | 1,371,600 |
| 2021-08-01 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 46,403 | .00 | 0 |
| 2021-07-30 | Dubow Adam (SVP,ChiefCompliance&EthicsOff.) | Sale | 2,466 | 67.90 | 167,441 |
| 2021-07-30 | Vessey Rupert (EVP, Research & Early Dev.) | Sale | 158,393 | 68.05 | 10,777,851 |
| 2021-07-30 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 150,967 | 57.02 | 8,608,591 |
| 2021-07-30 | Von Autenried Paul (EVP, Chief Information Officer) | Sale | 25,000 | 68.06 | 1,701,375 |
| 2021-07-30 | Leung Sandra (EVP, General Counsel) | Sale | 29,390 | 68.04 | 1,999,695 |
| 2021-07-01 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 9,356 | .00 | 0 |
| 2021-07-01 | Santiago Karen Murphy (SVP & Controller) | Option Ex | 1,069 | .00 | 0 |
| 2021-06-13 | Bonney Michael W | Option Ex | 902 | .00 | 0 |
| 2021-06-03 | Eid Joseph (SVP,Head Glob. Medical Affairs) | Option Ex | 2,154 | .00 | 0 |
| 2021-06-03 | Haller Julia A | Option Ex | 2,949 | .00 | 0 |
| 2021-06-03 | Bonney Michael W | Option Ex | 2,949 | .00 | 0 |
| 2021-05-10 | Eid Joseph (SVP,Head Glob. Medical Affairs) | Sale | 1,118 | 65.00 | 72,670 |
| 2021-05-10 | Schmukler Louis S (EVP,Pres.,Glob.Prod. & Supply) | Sale | 15,000 | 65.25 | 978,750 |
| 2021-05-08 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 17,245 | .00 | 0 |
| 2021-05-05 | Dubow Adam (SVP,ChiefCompliance&EthicsOff.) | Sale | 3,119 | 64.21 | 200,270 |
| 2021-05-05 | Vessey Rupert (EVP, Research & Early Dev.) | Sale | 30,546 | 64.29 | 1,963,802 |
| 2021-04-01 | Mily Elizabeth (EVP, Strategy & BD) | Option Ex | 6,346 | .00 | 0 |
| 2021-03-22 | Caforio Giovanni (Chairman and CEO) | Sale | 25,000 | 62.20 | 1,555,000 |
| 2021-03-10 | Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) | Option Ex | 4,189 | .00 | 0 |
| 2021-03-10 | Eid Joseph (SVP,Head Glob. Medical Affairs) | Option Ex | 6,134 | .00 | 0 |
| 2021-03-10 | Dubow Adam (SVP,ChiefCompliance&EthicsOff.) | Option Ex | 5,404 | .00 | 0 |
| 2021-03-10 | Santiago Karen Murphy (SVP & Controller) | Option Ex | 7,483 | .00 | 0 |
| 2021-03-10 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 7,423 | .00 | 0 |
| 2021-03-10 | Powell Ann (EVP, Chief Human Resources) | Option Ex | 29,835 | .00 | 0 |
| 2021-03-10 | Boerner Christopher S. (EVP, Chief Commercial Officer) | Option Ex | 25,215 | .00 | 0 |
| 2021-03-10 | Caforio Giovanni (Chairman and CEO) | Option Ex | 200,709 | .00 | 0 |
| 2021-03-10 | Schmukler Louis S (EVP,Pres.,Glob.Prod. & Supply) | Option Ex | 31,575 | .00 | 0 |
| 2021-03-10 | Von Autenried Paul (EVP, Chief Information Officer) | Option Ex | 20,302 | .00 | 0 |
| 2021-03-10 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 8,025 | .00 | 0 |
| 2021-03-10 | Leung Sandra (EVP, General Counsel) | Option Ex | 50,373 | .00 | 0 |
| 2021-03-01 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 23,349 | .00 | 0 |
| 2021-03-01 | Elkins David V (EVP, Chief Financial Officer) | Option Ex | 24,579 | .00 | 0 |
| 2021-02-04 | Vessey Rupert (EVP, Research & Early Dev.) | Option Ex | 3,592 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
of BMY listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Bristol Myers Squibb Co (symbol BMY,
CIK number 14272) see
the Securities and Exchange Commission (SEC) website.